Product Data SheetProduct Name:CAS No.: Cat. No.:MWt:Formula:Purity :Abiraterone154229-19-3HY-70013349.51C24H31NO>98%Solubility:DMSO <1.2mg/mL Water<1.2mg/mL Ethanol <1.2mg/mLMechanisms: Pathways:Metabolism/Protease; Target:Cytochrome P450 Biological Activity:Abiraterone (CB7598) is a potent steroidal cytochrome P450 17alphahydroxylase17,20lyaseAbiraterone(CB-7598)isapotentsteroidalcytochromeP45017alpha-hydroxylase-1720-lyase(CYP17) inhibitor with an IC50 at 4 nM. Abiraterone is used in treatment of prostate cancer. IC50 value: Target: CYP17 Abiraterone, a potent suppressor of cytochrome P450 17 α-hydroxysteroid dehydrogenase-mediatedandrogen production, has heralded a new era in the hormonal treatment of men with metastaticCRPC. Abiraterone acetate is associated with hypokalaemia, hypertension, and fluid retention oroedema, secondary to its mechanism of action, and with cardiac adverse events and hepatotoxicity;however, in the phase III studies the incidences of the most frequently reported grade 3 or 4 adverseevents of special interest were relatively low....References:[1]. Pinto-Bazurco Mendieta, Mariano A. E.; Synthesis, Biological Evaluation, and MolecularModeling of Abiraterone Analogues: Novel CYP17 Inhibitors for the Treatment of Prostate Cancer.Journal of Medicinal Chemistry (2008), 51(16), 5009-5018.y(),(), [2]. Attard G et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in thetreatment of castration-resistant prostate cancer. J Clin Oncol. 2009 Aug 10;27(23):3742-8. [3]. Schweizer MT, Antonarakis ES. Abiraterone and other novel androgen-directed strategies forthe treatment of prostate cancer: a new era of hormonal therapies is born.Ther Adv Urol. 2012Aug;4(4):167-78. [4]. Abiraterone. After prostate cancer treatment failure: 4-month survival advantage.Prescrire Int.2012 Jun;21(128):147-9. [5]. Li R, et al. Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increa...Caution: Not fully tested. For research purposes onlyMedchemexpress LLCwww.medchemexpress.com